Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP

https://www.medscape.org/viewarticle/communicating-enhance-care-through-data-and-patient-2025a1000uqi?page=1%3Fsrc%3Dmkmcmr_reeng_recap_mscpedu_activity&uac=148436CN&sso=true Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Below are some key learning points to help reinforce the impact of this activity. ☑ Education on self-monitoring can increase patient empowerment. ☑ The cancer care team should implement shared decision-making for optimal patient outcomes. ☑ Benefits of transitioning from fulvestrant to oral selective estrogen receptor degraders (SERDs) include fewer clinic visits and more patient independence. ☑ Elacestrant and imlunestrant are 2 oral SERDs approved by the FDA for the treatment of ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancers with disease progression following at least 1 line of endocrine therapy. ☑ There are differences in toxicity profiles between the oral SERDs, which need to be managed accordingly.